Atlas Trials

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Clinical trial NCT04092179 · TERMINATED

Trial details

NCT number
NCT04092179
Sponsor
University Health Network, Toronto
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaRelapsed CancerRefractory CancerIDH2 Gene Mutation
Start date
2020-11-05
Primary completion
2023-10-26
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.